Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 46 for:    congenital CMV

Reducing Acquisition of CMV Through Antenatal Education (RACEFIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03511274
Recruitment Status : Recruiting
First Posted : April 27, 2018
Last Update Posted : September 18, 2019
Sponsor:
Collaborators:
University College, London
Kingston University
University of Cambridge
CMV Action
Information provided by (Responsible Party):
Christine Jones, St George's, University of London

Brief Summary:

The evidence to date indicates that educational strategies may be effective at reducing antenatal CMV infection, however these have not been tested in the UK.

In phase 1 of the study, the investigators will co-design an educational intervention with pregnant women and families affected by congenital CMV with the aim of reducing the risk of acquisition of CMV in pregnancy. In phase 2 of the study, the investigators will use this educational intervention in a randomised controlled trial (RCT) as part of a feasibility study to generate the data required for the design of a future main RCT. Should the future main RCT show that the educational intervention is effective in reducing the risk of primary CMV infection in pregnancy, the intervention could be rolled out in the National Health Service (NHS). This would have significant benefits to patients and the NHS. No other single cause of congenital defects and long-term developmental disability currently provides greater opportunity for improved outcomes than the prevention of congenital CMV, therefore trials designed to test prevention strategies should be a research priority for the NHS.


Condition or disease Intervention/treatment Phase
Cytomegalovirus Congenital Behavioral: Hygiene based educational film Not Applicable

Detailed Description:

Cytomegalovirus (CMV) is the most common infection to be contracted before birth (a congenital infection); overall, about 20% of babies infected in this way have permanent health problems, such as hearing loss, learning delay or physical impairments. CMV is not a well-known infection, despite the health problems it can cause. It is actually more common than Down's syndrome or spina bifida. Simple hygiene measures may reduce the risk of catching CMV infection whilst pregnant and therefore also the risk of congenital infection in the infant. In the UK, pregnant women are not routinely counselled about these hygiene measures.

Before a large-scale study can be performed in the UK to determine the effectiveness of an educational intervention in reducing CMV infection in pregnancy, educational materials need to be developed and tested to ensure the feasibility of such a large study.

In this feasibility study, the investigators will work with pregnant women and families affected by CMV to design and produce a short film appropriate for use in the NHS to educate women about these simple hygiene measures (phase 1 of the study). Working in partnership with members of the public will help us ensure the content is relevant, clear and sensitive.The film will subsequently be tested in a study where women are assigned by chance to the educational intervention or to continue with treatment as usual with information about vaccines already recommended within the NHS. This ensures both groups will get some benefit from the study.

This study will enable the investigators to work out the number of pregnant women who are at risk of contracting CMV, how many of these women would agree to take part and to calculate the number of people needed in a future main trial in order to come to a reliable answer. This feasibility study is therefore essential to the design of a large-scale future trial.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: CMV seronegative pregnant women will be randomised to one of two study arms: treatment as usual or the education intervention
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Reducing Acquisition of CMV Through Antenatal Education: A Feasibility Study to Assess an Educational Intervention to Prevent Cytomegalovirus Infection in Pregnancy
Actual Study Start Date : January 17, 2017
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : September 2020


Arm Intervention/treatment
Experimental: Hygiene based educational film
Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
Behavioral: Hygiene based educational film
Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.

No Intervention: Treatment as usual (TAU)
Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.



Primary Outcome Measures :
  1. Educational intervention development [ Time Frame: 3 years ]
    Develop and refinement of a film-based educational intervention in partnership with pregnant women and families affected by CMV


Secondary Outcome Measures :
  1. Proportion of women willing to be screened for CMV [ Time Frame: 1 year ]
    Proportion of women approached who are willing to have antenatal booking blood tested for CMV antibodies to determine serostatus

  2. Proportion of women seronegative at antenatal booking [ Time Frame: 1 year ]
    Proportion of women who have no evidence of previous CMV infection at the time of antenatal booking

  3. Proportion of women with primary CMV infection in the first trimester of pregnancy [ Time Frame: 1 year ]
    Proportion of women who have evidence of primary CMV infection within the first trimester of pregnancy

  4. Proportion of seronegative willing to be randomised to receive educational intervention or treatment as usual [ Time Frame: 1 year ]
    Proportion of seronegative pregnant women willing to participate in feasibility study, which includes randomisation to the educational intervention or treatment as usual

  5. Seroconversion rate [ Time Frame: 18 months ]
    Women will have a second blood sample tested at the end of pregnancy (between 34 weeks and delivery) to determine whether seroconversion has occurred. Seroconversion is the appearance of anti-CMV IgG antibodies in the serum of a person who did not have such antibodies previously. This will be the gold standard evidence for acquisition of primary infection and is the main outcome measure of the future main trial.

  6. Proportion of infants with congenital CMV [ Time Frame: 2 years ]
    The proportion of infants with a positive test for CMV in the first 21 days of life

  7. Measures of adherence [ Time Frame: 2 years ]
    Women in the treatment arm will be asked to a questionnaire to assess their perceptions of adherence to the advice given

  8. Change in knowledge [ Time Frame: 2 years ]
    Women will complete questionnaires before and after the intervention to assess changes in knowledge about CMV

  9. Knowledge of CMV risk reduction measures [ Time Frame: 2 years ]
    Women will complete questionnaires before and after the intervention to assess changes in knowledge about risk reduction measures and self-efficacy towards these

  10. Acceptability of prevention measures [ Time Frame: 2 years ]
    Women will complete questionnaires before and after the intervention to assess the acceptability of prevention measures and to identify barriers to adherence. Interviews will also be carried out to explore these in more depth.

  11. Acceptability of the educational intervention (film) [ Time Frame: 2 years ]
    Perceptions Perceptions and acceptability of the educational intervention will be explored in questionnaires and interviews

  12. Anxiety level [ Time Frame: 2 years ]
    Women in the treatment arm will complete the Perinatal Anxiety Screening Scale and Edinburgh Depression Scale to ensure that study participation does not increase anxiety.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

• Pregnant women who have children less than 3 years of age booking to St George's Hospital antenatal clinics

Exclusion Criteria:

  • Unwilling or unable to give informed consent
  • Unwilling or unable to commit to study procedures
  • Less than 18 years old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03511274


Contacts
Layout table for location contacts
Contact: Chrissie Jones, BMBS PhD +44 (0)208725382 cjones@sgul.ac.uk
Contact: Suzie Wrihgt +44 (0)208725382 swright@sgul.ac.uk

Locations
Layout table for location information
United Kingdom
St George's, University of London Recruiting
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
St George's, University of London
University College, London
Kingston University
University of Cambridge
CMV Action
Investigators
Layout table for investigator information
Principal Investigator: Chrissie E Jones, BMBS PhD St George's, University of London

Layout table for additonal information
Responsible Party: Christine Jones, Honorary Senior Lecturer & Consultant in Paediatric Infectious Diseases, St George's, University of London
ClinicalTrials.gov Identifier: NCT03511274     History of Changes
Other Study ID Numbers: PB-PG-0215-36120
First Posted: April 27, 2018    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Christine Jones, St George's, University of London:
Cytomegalovirus Congenital
CMV
Cytomegalovirus infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases